PDF(Pubmed)
Abstract：
BACKGROUND: The effects of female chromosomal polymorphisms (FCPs) on various aspects of reproductive health have been investigated, yet the findings are frequently inconsistent. This study aims to clarify the role of FCPs on the outcomes of in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
METHODS: This retrospective cohort study comprised 951 couples with FCPs and 10,788 couples with normal karyotypes who underwent IVF/ICSI treatment at Peking University Third Hospital between 2015 and 2021. The exposure was FCPs. The embryological outcomes and clinical outcomes were compared.
RESULTS: The FCPs, as a whole, compromised the oocyte maturation rate (76.0% vs. 78.8%, P = 0.008), while they did not adversely affect other IVF/ICSI outcomes. Further detailed analyses showed that every type of FCPs contributed to the lower oocyte maturation rate, particularly the rare FCPs (69.0% vs. 78.8%, P = 0.008). The female qh + was associated with a higher normal fertilization rate (63.0% vs. 59.2%, adjusted P = 0.022), a higher clinical pregnancy rate (37.0% vs. 30.7%, adjusted P = 0.048), and a higher live birth rate (27.0% vs.19.0%, adjusted P = 0.003) in couples undergoing IVF. Conversely, in couples undergoing ICSI, female qh + was found to be related to a lower normal fertilization rate (58.8% vs. 63.8%, P = 0.032), a comparable clinical pregnancy rate (25.7% vs. 30.9%, P = 0.289), and a comparable live birth rate (19.8% vs. 19.2%, P = 0.880) compared to the control group. Additionally, an increased risk of preterm birth was observed in women undergoing IVF with multiple polymorphisms (62.5% vs. 16.9%, adjusted P < 0.001) and in women undergoing ICSI with pstk+ (36.4% vs. 15.4%, P = 0.036).
CONCLUSIONS: Our research unravels the diverse impacts of various FCPs on IVF/ICSI outcomes, highlighting the detrimental effects of FCPs on oocyte maturation and the risk of preterm birth.
METHODS: This retrospective cohort study comprised 951 couples with FCPs and 10,788 couples with normal karyotypes who underwent IVF/ICSI treatment at Peking University Third Hospital between 2015 and 2021. The exposure was FCPs. The embryological outcomes and clinical outcomes were compared.
RESULTS: The FCPs, as a whole, compromised the oocyte maturation rate (76.0% vs. 78.8%, P = 0.008), while they did not adversely affect other IVF/ICSI outcomes. Further detailed analyses showed that every type of FCPs contributed to the lower oocyte maturation rate, particularly the rare FCPs (69.0% vs. 78.8%, P = 0.008). The female qh + was associated with a higher normal fertilization rate (63.0% vs. 59.2%, adjusted P = 0.022), a higher clinical pregnancy rate (37.0% vs. 30.7%, adjusted P = 0.048), and a higher live birth rate (27.0% vs.19.0%, adjusted P = 0.003) in couples undergoing IVF. Conversely, in couples undergoing ICSI, female qh + was found to be related to a lower normal fertilization rate (58.8% vs. 63.8%, P = 0.032), a comparable clinical pregnancy rate (25.7% vs. 30.9%, P = 0.289), and a comparable live birth rate (19.8% vs. 19.2%, P = 0.880) compared to the control group. Additionally, an increased risk of preterm birth was observed in women undergoing IVF with multiple polymorphisms (62.5% vs. 16.9%, adjusted P < 0.001) and in women undergoing ICSI with pstk+ (36.4% vs. 15.4%, P = 0.036).
CONCLUSIONS: Our research unravels the diverse impacts of various FCPs on IVF/ICSI outcomes, highlighting the detrimental effects of FCPs on oocyte maturation and the risk of preterm birth.
摘要：
背景：已经研究了女性染色体多态性（FCP）对生殖健康各个方面的影响，然而，调查结果往往不一致。本研究旨在阐明FCPs在体外受精（IVF）和胞浆内单精子注射（ICSI）结局中的作用。
方法：这项回顾性队列研究包括2015年至2021年在北京大学第三医院接受IVF/ICSI治疗的951对FCP夫妇和10,788对正常核型夫妇。暴露是FCP。比较胚胎学结果和临床结果。
结果：FCP，作为一个整体,卵母细胞成熟率受损(76.0%vs.78.8%,P=0.008),而对其他IVF/ICSI结局无不良影响.进一步的详细分析表明，每种类型的FCP都有助于较低的卵母细胞成熟率，特别是罕见的FCP(69.0%vs.78.8%,P=0.008)。女性qh+与较高的正常受精率相关(63.0%vs.59.2%,调整后的P=0.022)，更高的临床妊娠率(37.0%vs.30.7%,调整后的P=0.048)，和更高的活产率(27.0%vs.19.0%，在接受IVF的夫妇中，调整后的P=0.003）。相反，在接受ICSI的夫妇中，发现女性qh+与较低的正常受精率有关(58.8%与63.8%,P=0.032),具有可比性的临床妊娠率(25.7%与30.9%,P=0.289),和可比的活产率(19.8%与19.2%,P=0.880）与对照组相比。此外,在接受IVF的女性中观察到早产风险增加，并伴有多种多态性(62.5%vs.16.9%,调整后的P<0.001）和接受ICSI伴pstk+的女性（36.4%vs.15.4%,P=0.036)。
结论：我们的研究揭示了各种FCP对IVF/ICSI结局的不同影响，强调FCP对卵母细胞成熟和早产风险的有害影响。
方法：这项回顾性队列研究包括2015年至2021年在北京大学第三医院接受IVF/ICSI治疗的951对FCP夫妇和10,788对正常核型夫妇。暴露是FCP。比较胚胎学结果和临床结果。
结果：FCP，作为一个整体,卵母细胞成熟率受损(76.0%vs.78.8%,P=0.008),而对其他IVF/ICSI结局无不良影响.进一步的详细分析表明，每种类型的FCP都有助于较低的卵母细胞成熟率，特别是罕见的FCP(69.0%vs.78.8%,P=0.008)。女性qh+与较高的正常受精率相关(63.0%vs.59.2%,调整后的P=0.022)，更高的临床妊娠率(37.0%vs.30.7%,调整后的P=0.048)，和更高的活产率(27.0%vs.19.0%，在接受IVF的夫妇中，调整后的P=0.003）。相反，在接受ICSI的夫妇中，发现女性qh+与较低的正常受精率有关(58.8%与63.8%,P=0.032),具有可比性的临床妊娠率(25.7%与30.9%,P=0.289),和可比的活产率(19.8%与19.2%,P=0.880）与对照组相比。此外,在接受IVF的女性中观察到早产风险增加，并伴有多种多态性(62.5%vs.16.9%,调整后的P<0.001）和接受ICSI伴pstk+的女性（36.4%vs.15.4%,P=0.036)。
结论：我们的研究揭示了各种FCP对IVF/ICSI结局的不同影响，强调FCP对卵母细胞成熟和早产风险的有害影响。
